This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
ProDex (PDEX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Patterson Cos. (PDCO) Up 0.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Patterson Cos. (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Henry Schein (HSIC) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
WST Stock Declines in Pre-Market Despite Q4 Earnings Beat, Margins Down
by Zacks Equity Research
West Pharmaceutical's overall top line in the fourth quarter of 2024 continues to benefit from revenue growth in its Proprietary Products segment.
West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 4% and 1.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical Services eyes fourth-quarter growth amid pharma stabilization, biologics rebound & contract manufacturing gains. Can WST sustain its momentum?
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 15.10% and 1.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings?
by Zacks Equity Research
The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory market dynamics.
Pro-Dex, Inc. (PDEX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ProDex (PDEX) delivered earnings and revenue surprises of 60.53% and 21.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
by Zacks Equity Research
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
LH vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. WST: Which Stock Is the Better Value Option?
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
by Zacks Equity Research
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
Strong Segmental Sales to Drive Cooper Companies Q4 Earnings?
by Zacks Equity Research
COO's fiscal fourth-quarter results are likely to reflect segmental strength.
Macro Challenges to Hurt Patterson Companies' Q2 Earnings?
by Zacks Equity Research
PDCO's fiscal second-quarter results are likely to reveal a decline in both the Dental and Animal Health segments, reflecting challenges like moderating traffic to clinics.
MMSI or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MMSI vs. WST: Which Stock Is the Better Value Option?
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
by Zacks Equity Research
WST continues to gain momentum due to its strength in the Pharma market unit. However, decline across its Generics and Biologics business units is concerning.
The Zacks Analyst Blog The Gorman-Rupp, Kontoor Brands, Kontoor Brands and Standex International
by Zacks Equity Research
The Gorman-Rupp, Kontoor Brands, Kontoor Brands and Standex International are included in this Analyst Blog.
Buy These 4 Stocks With New Dividend Hikes Amid Market Volatility
by Ritujay Ghosh
Stocks like GRC, KTB, WST and SXI recently announced dividend hikes.
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 22.52% and 5.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 1.73% and 1.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for West Pharmaceutical in Q3 Earnings?
by Zacks Equity Research
WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.
Earnings Preview: West Pharmaceutical Services (WST) Q3 Earnings Expected to Decline
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of -14.12% and 4.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?